Remy Castellano
Marseille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranostics.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: January 15, 2026
CRL2FEM1B uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer.
Journal: Molecular cell
Published: May 08, 2025
Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1.
Journal: British journal of haematology
Published: December 21, 2024
Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML.
Journal: EMBO molecular medicine
Published: October 18, 2024
Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer.
Journal: Nature communications
Published: August 15, 2024
The LRP4/YAP axis drives the radiation-tolerant persister (RTP) cell state in breast cancer.
Journal: Theranostics
Published: July 24, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.
Journal: Cancer research communications
Published: March 22, 2024
DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing.
Journal: Scientific reports
Published: February 21, 2024
mTert induction in p21-positive cells counteracts capillary rarefaction and pulmonary emphysema.
Journal: EMBO reports
Published: October 06, 2023
INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia Treatment.
Journal: Molecular cancer therapeutics
Published: August 22, 2023
Downregulation of stromal syntenin sustains AML development.
Journal: EMBO molecular medicine
Published: February 15, 2023
Last Updated: 09/26/2026